Cerus Corp (NASDAQ:) Chief Financial Officer Kevin Dennis Green recently sold shares of the company’s stock totaling $84,881, according to the company’s latest Form 4 filing with the Securities and Exchange Commission. The transactions occurred on March 13 and 14, with shares sold at prices ranging from $1.9744 to $2.0153 per share.
On March 13, Greene sold 21,058 shares of Cerus Corp common stock at an average price of approximately $2.0153 per share. The next day, he sold another 21,497 shares at an average price of $1.9744 per share. These sales were made in multiple transactions at varying prices within stated ranges.
The sales were part of a predetermined plan under Rule 10b5-1, which allows company insiders to make a predetermined plan to sell shares at a time when they do not have material non-public information. The plan was put in place to cover statutory withholding tax obligations and related brokerage commissions upon the transfer of certain restricted stock units. It is important to note that such transactions do not necessarily indicate a lack of confidence in the company by management; rather, they are often part of regular financial planning strategies.
Prior to these transactions, Green acquired 21,666 shares through the vesting of restricted stock units as set forth on the same Form 4. These units represent a conditional right to receive shares of Cerus Corp common stock and are part of an executive compensation package that vests over a specified period of time. period of time.
Following these transactions, Green’s direct ownership of Cerus Corp was increased to 618,750 shares of common stock.
Investors often track insider buying and selling as it can provide insight into management’s views on a company’s future prospects. However, it is also important to consider the broader context in which these transactions occur, including compensation plans and personal financial management.
Cerus Corp, based in Concord, California, specializes in the development and commercialization of surgical and medical instruments and devices. The company’s primary focus is on products that can improve blood safety and provide innovative medical solutions.
InvestingAbout Insights
Cerus Corp (NASDAQ:CERS) has experienced significant share price volatility recently, as reflected in InvestingPro’s real-time metrics. The company’s market capitalization currently stands at around $358.94 million. Despite the fluctuations, the company’s liquid assets reportedly exceed its short-term liabilities, suggesting some financial stability in the face of market pressures.
Cerus Corp’s current P/B ratio is relatively high at 6.82 as of the trailing twelve months ended fourth quarter of 2023. This metric, which compares a company’s market value to its book value, can indicate that the stock is trading at a premium to its net asset value. Additionally, the P/E ratio (adjusted) for the same period is -10.2, which could indicate that investors are expecting future growth, despite the company not being profitable over the past twelve months.
InvestingPro’s tips show that analysts don’t expect Cerus Corp to be profitable this year and that the stock has performed poorly over the past month, with a total monthly return of -17.15%. Additionally, the company does not pay dividends to shareholders, which is an important factor for income-oriented investors.
For those who want to dig deeper into Cerus Corp’s financials and stock performance, additional InvestingPro tips are available. Investors can access these tips and a wealth of other detailed financial information by visiting https://www.investing.com/pro/CERS. Use coupon code PRONEWS24 to receive an additional 10% discount on annual or two-year Pro and Pro+ subscriptions, giving you even more information to make your investment decisions. With the latest data and analysis at your fingertips, you can better assess the potential risks and rewards of Cerus Corp. stock.
This article was created with the help of AI and reviewed by an editor. For more information please see our Terms and Conditions.